Urologic cancers — tumors of the bladder, kidneys, adrenal glands, and genitals — are among the most common cancers in the United States. According to the American Cancer Society:
- About one in seven men will be diagnosed with prostate cancer in their lifetime.
- Roughly, 81,000 new cases of bladder cancer will be diagnosed this year.
- Since the 1990s, the rate of new kidney cancers have been rising, with an estimated 63,000 new cases projected for this year.
At NewYork-Presbyterian, our urologic cancer team combines evidence-based medicine and cutting-edge research to detect and treat— and, in the future, prevent — urologic cancers. Our programs at NewYork-Presbyterian/Columbia University Irving Medical Center and NewYork-Presbyterian/Weill Cornell Medical Center use specialized instrumentation, such as genomic technologies, and advanced therapies aimed at stopping the growth and spread of the tumors.
Our Approach to Cancer Care
The one-size-fits-all approach to patient care rarely works, particularly when it comes to cancer treatment. The oncology doctors and scientists at NewYork-Presbyterian and our academic partners, Columbia University Irving Medical Center and Weill Cornell Medicine, recognize the key to treating and preventing cancers is taking a closer look at our patients. Through more patient-centric care, NewYork-Presbyterian is on the cusp of revolutionizing cancer care with new tools to improve medical decision-making.
Studying the systems. Using RNA-sequencing, our clinicians have examined immune cells from bladder cancer, kidney cancer, and prostate cancer. This allows our team to understand better how the genes behaves, adapts to changing environments, and breaks apart.
Improving early detection. Our clinicians and scientists are pursuing innovative investigations and initiatives addressing challenges to early detection of prostate cancer and extending survival for those with metastatic disease.
Developing new treatments and therapies. Our research teams are developing molecularly based clinical trials to bring more effective treatments to patients faster. So if a patient’s tumor has a mutation, we can identify the most effective treatment strategy or clinical trial based on their molecular profile.
Next Generation Therapeutic Care through Research
As an academic medical center, research is a cornerstone of our institution. Through our laboratory research programs at Columbia University Irving Medical Center and Weill Cornell Medicine, we are able to create human models to study and develop immunotherapy approaches. With more than 500 active clinical trials involving current patients, we are rapidly moving from hypothesis to proven therapy.
In 2016, NewYork-Presbyterian was awarded a $45 million grant by the National Institutes of Health to enable researchers to enroll patients in the All of Us Research Program. All of Us is aimed at using precision medicine to improve research at the intersection of human biology, behavior, genetics, environment, data science, and computation to develop more efficient ways to treat certain cancers and other diseases. To learn more about the All of Us Research Program, visit allofus.nih.gov.
Herbert Irving Comprehensive Cancer Center NewYork-Presbyterian/Columbia
Please call to refer a patient or schedule an appointment.